Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer by S. Lebdai et al.
Potentiating vascular-targeted photodynamic therapy
through CSF-1R modulation of myeloid cells in a preclinical
model of prostate cancer
Submitted by Stéphanie Pinot on Thu, 06/20/2019 - 11:13
Titre Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation ofmyeloid cells in a preclinical model of prostate cancer
Type de
publication Article de revue
Auteur
Lebdai, Souhil [1], Gigoux, Mathieu [2], Alvim, Ricardo [3], Somma, Alexander J [4],
Nagar, Karan [5], Azzouzi, Abdel Rahmene [6], Cussenot, Olivier [7], Merghoub, Taha
[8], Wolchok, Jedd D [9], Scherz, Avigdor [10], Kim, Kwanghee [11], Coleman, Jonathan
A [12]
Editeur Taylor & Francis
Type Article scientifique dans une revue à comité de lecture
Année 2019
Langue Anglais
Date 2019
Numéro 6
Pagination e1581528
Volume 8
Titre de la
revue Oncoimmunology
ISSN 2162-4011
Mots-clés CSF-1R [13], Immunotherapy [14], MDSCs [15], myeloid cells [16], Prostate cancer[17], Vascular-targeted photodynamic therapy [18], WST11 [19]
Résumé en
anglais
Vascular-targeted photodynamic therapy (VTP) induces rapid destruction of targeted
tissues and is a promising therapy for prostate cancer. However, the resulting immune
response, which may play an important role in either potentiating or blunting the
effects of VTP, is still incompletely understood. Myeloid cells such as myeloid-derived
suppressor cells (MDSCs) and macrophages are often found in tumors and are widely
reported to be associated with cancer angiogenesis, tissue remodeling, and
immunosuppression. These cells are also known to play a critical role in wound-
healing, which is induced by rapid tissue destruction. In this study, we investigated the
effects of VTP on the recruitment of tumor-infiltrating myeloid cells, specifically
MDSCs and tumor-associated macrophages (TAMs), in the Myc-Cap and TRAMP C2
murine prostate cancer models. We report that VTP increased the infiltration of
myeloid cells into the tumors, as well as their expression of CSF1R, a receptor required
for myeloid differentiation, proliferation, and tumor migration. As anti-CSF1R
treatment has previously been used to deplete these cells types in other murine models
of prostate cancer, we hypothesized that combining anti-CSF1R with VTP therapy
would lead to decreased tumor regrowth and improved survival. Importantly, we found
that targeting myeloid cells using anti-CSF1R in combination with VTP therapy
decreased the number of tumor MDSCs and TAMs, especially M2 macrophages, as well
as increased CD8 T cell infiltration, decreased tumor growth and improved overall
survival. These results suggest that targeting myeloid cells via CSF1R targeting is a
promising strategy to potentiate the anti-tumor effects of VTP.
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